Spectrum Pharma's cancer drug meets main goal in trial

April 23 Wed Apr 23, 2014 7:26am EDT

April 23 (Reuters) - Spectrum Pharmaceuticals said its experimental cancer drug was shown to be safe and effective in a mid-stage trial.

Spectrum's drug, Captisol-enabled melphalan, is an intravenous formulation of a common chemotherapy drug melphalan, and is being tested in multiple myeloma patients undergoing stem cell transplants.

The company said it expects to file for a regulatory approval in the third quarter.

(Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.